Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab
Reeve, Carol, Whitehall, John, Buettner, Petra, Norton, Robert, Reeve, David, and Francis, Fleur (2006) Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. Journal of Paediatrics and Child Health, 42 (5). pp. 253-258.
PDF (Published Version)
Restricted to Repository staff only
Background: a monoclonal antibody, palivizumab, directed against respiratory syncytial virus (RSV) has been shown to decrease hospitalisation rates. Because of its expense, the cost-effectiveness of this agent should be determined for high-risk groups.
Aim: to determine characteristics of RSV infection in Townsville and the economic feasibility of palivizumab immunoprophylaxis in high-risk groups.
Methods: cases of RSV-positive bronchiolitis were retrospectively identified. Cases were grouped according to recognised risk factors. The hypothetical costs of palivizumab immunoprophylaxis for infants at risk were calculated.
Results: the rate of hospitalisation with RSV-positive lower respiratory tract infection was 22 per 1000 live births but increased to 50 per 1000 among Indigenous babies born weighing <2500 g. The cost of preventing an admission in each of the identified high-risk groups, based on drug costs alone, ranged from A$69 861 to A$88 547.
Conclusion: Palivizumab was not cost-effective in the prophylaxis of RSV in the high-risk group of infants tested here.
|Item Type:||Article (Refereed Research - C1)|
|Keywords:||palivizumab; prophylaxis; respiratory syncytial virus|
|Date Deposited:||26 Nov 2009 05:40|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1114 Paediatrics and Reproductive Medicine > 111403 Paediatrics @ 80%
11 MEDICAL AND HEALTH SCIENCES > 1117 Public Health and Health Services > 111716 Preventive Medicine @ 20%
|SEO Codes:||92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920109 Infectious Diseases @ 50%
92 HEALTH > 9205 Specific Population Health (excl. Indigenous Health) > 920501 Child Health @ 30%
92 HEALTH > 9203 Indigenous Health > 920399 Indigenous Health not elsewhere classified @ 20%
|Citation Count from Web of Science||